步长制药: 山东步长制药股份有限公司第五届董事会第二十八次会议决议公告

Core Viewpoint - The company has approved several key resolutions during its board meeting, including the signing of an exclusive supply agreement for Efparepoetin alfa and the transfer of equity stakes in its subsidiary [1][2]. Group 1: Exclusive Supply Agreement - The company’s subsidiary, Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd., plans to sign an exclusive supply agreement with GOODFELLOW PHARMA CORPORATION for the drug Efparepoetin alfa in the Philippines [1]. - GOODFELLOW will act as the exclusive agent in the target region for the registration, clinical trials, promotion, distribution, and sales of Efparepoetin alfa [1]. Group 2: Equity Transfer - The company intends to transfer 2.00% of the equity in its subsidiary Jinan Buchang Caikan Trading Co., Ltd. to He Tao, and another 2.00% to Fang Ke Rui, while 1.00% will be transferred to 1929 Health Technology (Guangzhou) Co., Ltd. [2]. - The transfer price for these equity stakes is set at 0 yuan, resulting in the company retaining a 90% ownership stake in Buchang Caikan after the transfers [2]. Group 3: Name and Address Change - The subsidiary Jinan Buchang Caikan Trading Co., Ltd. plans to change its registered address and name for operational management needs [3]. - This change has also been approved by the board and will be submitted for further review [3].